United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Eversept Partners LP

Eversept Partners LP decreased its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 66.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 43,703 shares of the biotechnology company’s stock after selling 87,246 shares during the period. United Therapeutics makes up approximately 1.4% of Eversept Partners LP’s holdings, making the stock its 14th largest position. Eversept Partners LP’s holdings in United Therapeutics were worth $15,420,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in UTHR. Signaturefd LLC grew its stake in shares of United Therapeutics by 4.7% in the 4th quarter. Signaturefd LLC now owns 663 shares of the biotechnology company’s stock valued at $234,000 after purchasing an additional 30 shares during the last quarter. Parallel Advisors LLC increased its stake in shares of United Therapeutics by 2.8% during the fourth quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company’s stock worth $385,000 after acquiring an additional 30 shares during the period. Anchor Investment Management LLC lifted its position in United Therapeutics by 12.0% in the fourth quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 30 shares during the period. Great Lakes Advisors LLC boosted its holdings in United Therapeutics by 1.6% in the 4th quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company’s stock valued at $697,000 after purchasing an additional 31 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund increased its position in United Therapeutics by 0.4% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company’s stock worth $3,214,000 after purchasing an additional 33 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Buying and Selling at United Therapeutics

In related news, Director Tommy G. Thompson sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the completion of the sale, the director now directly owns 8,480 shares in the company, valued at approximately $2,703,424. This trade represents a 22.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $370.71, for a total transaction of $3,707,100.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares in the company, valued at approximately $955,319.67. This represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 81,500 shares of company stock valued at $27,322,440 in the last three months. 11.90% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of analysts recently weighed in on UTHR shares. JPMorgan Chase & Co. decreased their price target on United Therapeutics from $357.00 to $355.00 and set an “overweight” rating on the stock in a research note on Monday. Bank of America upgraded shares of United Therapeutics from an “underperform” rating to a “neutral” rating and set a $314.00 price target for the company in a research report on Monday. UBS Group lifted their price objective on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. HC Wainwright reissued a “buy” rating and issued a $425.00 price objective on shares of United Therapeutics in a research note on Thursday, February 27th. Finally, StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, April 17th. Three investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $395.67.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR opened at $284.25 on Tuesday. The firm has a market cap of $12.77 billion, a P/E ratio of 12.48, a PEG ratio of 0.97 and a beta of 0.63. The stock has a fifty day moving average price of $314.88 and a two-hundred day moving average price of $348.12. United Therapeutics Co. has a 1 year low of $233.28 and a 1 year high of $417.82.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, beating the consensus estimate of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $735.90 million during the quarter, compared to the consensus estimate of $734.74 million. During the same period in the prior year, the business posted $4.36 earnings per share. On average, research analysts predict that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.